Jessica Ley

Washington University in St. Louis

Papers

1

Total Citations

5

H-Index

1

About

Dr. Jessica Ley is a leading clinical researcher in head and neck oncology, with a focus on human papillomavirus-positive oropharyngeal squamous-cell carcinoma (HPV+ OPSCC). Her work centers on refining treatment paradigms to reduce long-term toxicity without compromising survival outcomes. Dr. Ley’s most notable contribution is her leadership of a non-randomized, multi-arm Phase 2 trial investigating risk-directed, de-escalated adjuvant therapy for surgically resected locally advanced HPV+ OPSCC. This landmark study, published in 2024, demonstrated that tailored, less intensive post-operative regimens can maintain excellent disease control while minimizing side effects—a paradigm-shifting approach for patients with favorable prognosis. The work has already garnered 5 citations, signaling its rapid integration into clinical discourse. Dr. Ley’s research is instrumental in moving the field toward personalized, de-escalation strategies that prioritize quality of life, and her findings are shaping national treatment guidelines. Her dedication to balancing efficacy with survivorship makes her a pivotal figure in modern head and neck cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 Trial
5 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Washington University in St. Louis

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago